According to Bloomberg, Cevian, one of UBS's major shareholders, sold over a quarter of its stake in UBS in recent months. Over the same period, the outlook for UBS regarding the prospective application of capital regulatory rules has turned unfavorable. The report did not disclose the transaction amount or the remaining shareholding percentage in the current summary.